Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.56 |
| ▸ | FABP7 | O15540 | 2/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10405601 | 0.91 | FABP5 (0.56) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL30253705 | 0.90 | FABP5 (0.52) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL28347737 | 0.89 | KMT2A (0.52) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL31572314 | 0.89 | KMT2A (0.52) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL4906918 | 0.88 | KMT2A (0.52) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL44676 | 0.88 | KMT2A (0.58) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL28384837 | 0.88 | KMT2A (0.51) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL3630096 | 0.87 | KMT2A (0.48) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL4728768 | 0.87 | KMT2A (0.48) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL2782675 | 0.86 | KMT2A (0.56) | KMT2AFABP5FABP7EPHX2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230141981-A1 | NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS | Shanghai MICURX Pharmaceuticals Co., Ltd. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20140238939-A1 | IMMOBILIZATION OF ANTIMICROBIAL POLYMERS ON RO MEMBRANE TO REDUCE BIOFILM GROWTH AND BIOFOULING | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141981-A1 | NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS | GLS, ATP6V1B1, KRAS | KMT2A 2683/4885FABP5 629/4885FABP7 1458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.